CSPAN3 Medical Product Development And Innovation December 12, 2017
So doctor, pharmaceutical Development Today frequently involves what is called shooting in the dark, making key decisions can with very limited data. For example, decisions including indication selection, dosage end points and Inclusion Exclusion criteria. The data that informs such decisions lies in inaccessible silence at least to most stake holders. It includes to hire longer time lines. Now the fda already has much of this data, this otherwise siloed information. So my question for you is has the fda taken any steps in ago ri gaiting to improve the process and if not would the fda be willi...